
Carbidopa and Levodopa

Quality Solutions

Category: Antiparkinson Agents



USP can support your development and manufacturing activities on Carbidopa and Levodopa-based medicines with these existing and upcoming standards.



Official and Proposed Documentary Standards and Associated Physical Materials

MONOGRAPH 1

CARBIDOPA AND LEVODOPA EXTENDED-RELEASE TABLETS Official as of 01-Aug-2018	Ì
USP Carbidopa RS	<u>USP-1095506</u>
USP Levodopa RS	<u>USP-1361009</u>
USP Levodopa Related Compound B RS	<u>USP-1420006</u>

MONOGRAPH 2

CARBIDOPA AND LEVODOPA ORALLY DISINTEGRATING TABLETS Official as of 01-May-2022	
USP Carbidopa RS	<u>USP-1095506</u>
USP Levodopa RS	<u>USP-1361009</u>
USP Methyldopa RS	<u>USP-1426002</u>
USP Levodopa Related Compound A RS	<u>USP-1361010</u>
USP Levodopa Related Compound B RS	<u>USP-1420006</u>

MONOGRAPH 3

CARBIDOPA AND LEVODOPA TABLETS NEW Official as of 01-Oct-2023	
USP Carbidopa RS	<u>USP-1095506</u>
USP Levodopa RS	<u>USP-1361009</u>
USP Levodopa Related Compound B RS	<u>USP-1420006</u>

^{*} Documents in PF Online are not official and not suitable to demonstrate compliance. They may never become official.

01-Dec-2023. For publications related to **Carbidopa and Levodopa** in *PF* online after this date, please visit the integrated *USP-NF/PF* online.

Disclaimer: USP Quality Solution Sheets are provided as a convenience and for informational purposes only. Labmix24 makes reasonable efforts to provide correct information but assumes no liability for the completeness, timeliness or accuracy of the information contained in each QSS. It is the responsibility of the user to verify the information. The US Pharmacopeia remains the official source of this information.

